Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R John Simes

Showing results (21-30 of 80) with videos related to

Pageof 8
Sort By:
JCO Precision Oncology|July 6, 2026
Time to Treatment Failure as an End Point in Pragmatic Oncology Trials: Association With Progression-Free Survival Across Randomized StudiesJanene Dalrymple, Rebecca Symons, Katrin M Sjoquist, et al.
JCO Precision Oncology|January 11, 2024
Validity and Efficiency of Progression-Free Survival-2 as a Surrogate End Point for Overall Survival in Advanced Cancer Randomized TrialsRachel Woodford, Deborah Zhou, Peey-Sei Kok, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|March 28, 2009
Relationships of HDL cholesterol, ApoA-I, and ApoA-II with homocysteine and creatinine in patients with type 2 diabetes treated with fenofibrateMarja-Riitta Taskinen, David R Sullivan, Christian Ehnholm, et al.
JCO Precision Oncology|January 8, 2024
Framework for the Use of External Controls to Evaluate Treatment Outcomes in Precision Oncology TrialsDerrick H W Siu, Frank P Y Lin, Doah Cho, et al.
European Journal of Cancer (Oxford, England : 1990)|November 13, 2013
The cost effectiveness of bevacizumab when added to capecitabine, with or without mitomycin-C, in first line treatment of metastatic colorectal cancer: results from the Australasian phase III MAX studyHannah E Carter, Diana Zannino, R John Simes, et al.
The American Journal of Clinical Nutrition|June 9, 2005
Relation of diet to cardiovascular disease risk factors in subjects with cardiovascular disease in Australia and New Zealand: analysis of the Long-Term Intervention with Pravastatin in Ischaemic Disease trialPaul J Nestel, Katrine Baghurst, David M Colquhoun, et al.
European Heart Journal|October 18, 2007
Cardiovascular disease on a global scale: defining the path forward for research and practiceDaniel B Mark, Frans J Van de Werf, R John Simes, et al.
Diabetes Care|September 30, 2003
Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trialAnthony Keech, David Colquhoun, James Best, et al.
Cancer|January 5, 2022
The validity of progression-free survival 2 as a surrogate trial end point for overall survivalRachel G Woodford, Deborah D-X Zhou, Peey-Sei Kok, et al.
European Heart Journal|November 14, 2003
Depression and cardiovascular morbidity and mortality: cause or consequence?Ralph A H Stewart, Fiona M North, Teena M West, et al.
Pageof 8

Showing results (21-30 of 80) with videos related to

Sort By:
Pageof 8
JCO Precision Oncology|July 6, 2026
Time to Treatment Failure as an End Point in Pragmatic Oncology Trials: Association With Progression-Free Survival Across Randomized StudiesJanene Dalrymple, Rebecca Symons, Katrin M Sjoquist, et al.
JCO Precision Oncology|January 11, 2024
Validity and Efficiency of Progression-Free Survival-2 as a Surrogate End Point for Overall Survival in Advanced Cancer Randomized TrialsRachel Woodford, Deborah Zhou, Peey-Sei Kok, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|March 28, 2009
Relationships of HDL cholesterol, ApoA-I, and ApoA-II with homocysteine and creatinine in patients with type 2 diabetes treated with fenofibrateMarja-Riitta Taskinen, David R Sullivan, Christian Ehnholm, et al.
JCO Precision Oncology|January 8, 2024
Framework for the Use of External Controls to Evaluate Treatment Outcomes in Precision Oncology TrialsDerrick H W Siu, Frank P Y Lin, Doah Cho, et al.
European Journal of Cancer (Oxford, England : 1990)|November 13, 2013
The cost effectiveness of bevacizumab when added to capecitabine, with or without mitomycin-C, in first line treatment of metastatic colorectal cancer: results from the Australasian phase III MAX studyHannah E Carter, Diana Zannino, R John Simes, et al.
The American Journal of Clinical Nutrition|June 9, 2005
Relation of diet to cardiovascular disease risk factors in subjects with cardiovascular disease in Australia and New Zealand: analysis of the Long-Term Intervention with Pravastatin in Ischaemic Disease trialPaul J Nestel, Katrine Baghurst, David M Colquhoun, et al.
European Heart Journal|October 18, 2007
Cardiovascular disease on a global scale: defining the path forward for research and practiceDaniel B Mark, Frans J Van de Werf, R John Simes, et al.
Diabetes Care|September 30, 2003
Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trialAnthony Keech, David Colquhoun, James Best, et al.
Cancer|January 5, 2022
The validity of progression-free survival 2 as a surrogate trial end point for overall survivalRachel G Woodford, Deborah D-X Zhou, Peey-Sei Kok, et al.
European Heart Journal|November 14, 2003
Depression and cardiovascular morbidity and mortality: cause or consequence?Ralph A H Stewart, Fiona M North, Teena M West, et al.
Pageof 8